Patents by Inventor Motomu Kanai
Motomu Kanai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10526348Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.Type: GrantFiled: March 21, 2017Date of Patent: January 7, 2020Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
-
Patent number: 10406141Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.Type: GrantFiled: February 26, 2016Date of Patent: September 10, 2019Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Yoshinori Fukui, Takehito Uruno, Motomu Kanai, Shigeki Matsunaga, Takahiro Shirai, Shigeyuki Yokoyama, Teruki Honma, Mutsuko Niino, Daisuke Takaya
-
Patent number: 10280142Abstract: There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound.Type: GrantFiled: November 21, 2017Date of Patent: May 7, 2019Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Yoichiro Kuninobu, Motomu Kanai, Haruka Ida, Mitsumi Nishi
-
Publication number: 20190100518Abstract: The present invention relates to a cross-linking agent for cross-linking an indole-structure-containing molecule to a desired molecule, the cross-linking agent containing, as an effective component, a radical compound having an N-oxy radical group and a group capable of bonding to the desired molecule.Type: ApplicationFiled: March 8, 2017Publication date: April 4, 2019Applicant: The University of TokyoInventors: Motomu KANAI, Kounosuke OISAKI, Yohei SEKI, Daisuke SASAKI, Takashi ISHIYAMA
-
Publication number: 20190100537Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.Type: ApplicationFiled: March 21, 2017Publication date: April 4, 2019Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu KANAI, Yohei SOMA, Jizhi NI, Atsuhiko TANIGUCHI
-
Publication number: 20190047985Abstract: An artificial catalyst system which can acylate chromosome proteins with high selectivity has successfully been established by using a combination of an acyl CoA activating catalyst having target acylation area binding ability and acyl CoA or a derivative thereof.Type: ApplicationFiled: August 29, 2016Publication date: February 14, 2019Applicant: THE UNIVERSITY OF TOKYOInventors: Motomu KANAI, Shigehiro KAWASHIMA, Kenzo YAMATSUGU, Yoshifumi AMAMOTO, Yuki AOI, Hiroki SUTO, Nozomu NAGASHIMA, Hitoshi KURUMIZAKA, Akihisa OSAKABE, Yasuhiro ARIMURA
-
Patent number: 10188671Abstract: Provided is a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an A? peptide, but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related diseases.Type: GrantFiled: March 4, 2016Date of Patent: January 29, 2019Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Yusuke Shimizu, Atsuhiko Taniguchi, Kounosuke Oisaki, Yoichiro Kuninobu
-
Publication number: 20180312558Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).Type: ApplicationFiled: June 26, 2018Publication date: November 1, 2018Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Daisuke Sasaki
-
Patent number: 10035831Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).Type: GrantFiled: June 13, 2014Date of Patent: July 31, 2018Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Daisuke Sasaki
-
Patent number: 10029968Abstract: Provided is a process for producing an optically active hydroxyaldehyde or aminohydroxyaldehyde. The process for producing an optically active hydroxyaldehyde or aminohydroxyaldehyde is characterized by reacting an aldehyde or an imine with a boric acid enol ester in the presence of a copper compound and an optically active bidentate phosphine compound.Type: GrantFiled: August 31, 2015Date of Patent: July 24, 2018Assignee: Takasago International CorporationInventors: Motomu Kanai, Shigeki Matsunaga
-
Patent number: 9932333Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A? peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.Type: GrantFiled: July 15, 2015Date of Patent: April 3, 2018Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Yusuke Shimizu
-
Publication number: 20180072672Abstract: There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound.Type: ApplicationFiled: November 21, 2017Publication date: March 15, 2018Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Yoichiro KUNINOBU, Motomu Kanai, Haruka Ida, Mitsumi Nishi
-
Patent number: 9908852Abstract: There are provided a compound capable of being a novel ligand allowing regioselective borylation to be performed in the aromatic borylation reaction, and a catalyst using the same compound.Type: GrantFiled: January 29, 2015Date of Patent: March 6, 2018Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Yoichiro Kuninobu, Motomu Kanai, Haruka Ida, Mitsumi Nishi
-
Publication number: 20180042948Abstract: Provided are a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an A? peptide but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related-diseases.Type: ApplicationFiled: March 4, 2016Publication date: February 15, 2018Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu KANAI, Yohei SOMA, Yusuke SHIMIZU, Atsuhiko TANIGUCHI, Kounosuke OISAKI, Yoichiro KUNINOBU
-
Publication number: 20180028515Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.Type: ApplicationFiled: February 26, 2016Publication date: February 1, 2018Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Yoshinori FUKUI, Takehito URUNO, Motomu KANAI, Shigeki MATSUNAGA, Takahiro SHIRAI, Shigeyuki YOKOYAMA, Teruki HONMA, Mutsuko NIINO, Daisuke TAKAYA
-
Patent number: 9796677Abstract: Provided is a novel compound which has an excellent A? aggregation inhibitory effect and is useful as a pharmaceutical. An amide compound represented by the formula (1) or a salt thereof, wherein Z represents CH or N; A and B are the same or different and each represents —CH2—, —O—, —S—, or —NH—; R1 and R2 are the same or different and each represents a branched alkyl group, a branched alkenyl group, an optionally substituted aromatic hydrocarbon group, an optionally substituted aralkyl group, an optionally substituted cycloalkyl group, or an optionally substituted aromatic heterocyclic group; and R3 represents a branched alkyl group, a branched alkenyl group, an optionally substituted cycloalkyl group, or an optionally substituted aralkyl group.Type: GrantFiled: December 9, 2014Date of Patent: October 24, 2017Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Tadamasa Arai, Takushi Araya
-
Publication number: 20170297990Abstract: Provided is a process for producing an optically active hydroxyaldehyde or aminohydroxyaldehyde. The process for producing an optically active hydroxyaldehyde or aminohydroxyaldehyde is characterized by reacting an aldehyde or an imine with a boric acid enol ester in the presence of a copper compound and an optically active bidentate phosphine compound.Type: ApplicationFiled: August 31, 2015Publication date: October 19, 2017Applicant: Takasago International CorporationInventors: Motomu Kanai, Shigeki Matsunaga
-
Patent number: 9745349Abstract: A cyclic peptide or a salt thereof of formula (1): X-Leu-Val-Y1-Y2 (1), where X is Lys, Arg, His, Ala, Gly, Ser, or Thr; and Y1 and Y2, which are identical to or different from each other, each represent a group represented by formula (2): where Ar1 represents an aromatic hydrocarbon group or an aromatic heterocyclic group; R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a haloalkyl group, an aromatic hydrocarbon group, or an aromatic heterocyclic group; and n is an integer from 0 to 2. In the cyclic peptide has an ?-amino group at the amino terminus of the amino acid sequence which is linked, via a peptide bond, to the carboxyl group at the carboxyl terminus of the amino acid sequence.Type: GrantFiled: October 18, 2013Date of Patent: August 29, 2017Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu Kanai, Yohei Soma, Tadamasa Arai, Daisuke Sasaki, Yuki Kobayashi
-
Publication number: 20170197956Abstract: It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A? peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R1 represents an optionally substituted hydrocarbon group; R2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R3 and R4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R2 and R4 optionally together form an alkylene group; and R5 represents an anion.Type: ApplicationFiled: July 15, 2015Publication date: July 13, 2017Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCYInventors: Motomu KANAI, Yohei SOMA, Atsuhiko TANIGUCHI, Yusuke SHIMIZU
-
Patent number: 9670255Abstract: It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.Type: GrantFiled: February 18, 2014Date of Patent: June 6, 2017Assignee: SAVID THERAPEUTICS INC.Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Tomohiro Yamamoto